NCT05766150

Brief Summary

This case-control study aims to investigate if oral microbioma is associated with developing oral (pre)malignant disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2021

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2021

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

February 22, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

March 13, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

March 13, 2023

Status Verified

March 1, 2023

Enrollment Period

2.6 years

First QC Date

February 22, 2023

Last Update Submit

March 10, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Association between oral microbioma and (pre)malignant disease.

    Prevalence of clusters of different oral pathogens will be displayed for patients with malignant disease, premalignant disease and no oral malignancy. Taxonomic representation of statistically and biologically consistent differences between patients with malignant disease, premalignant disease and no oral malignant disease will be displayed.

    Through study completion, an average of 3 years

Secondary Outcomes (2)

  • To describe the difference in oral microbioma between young (>40 years) patients with oral SCC and older (>40 years) patients with oral squamous cell carcinoma.

    Through study completion, an average of 3 years

  • To desribe the difference in oral microbioma and stage of disease upon presentation.

    Through study completion, an average of 3 years

Study Arms (3)

Patients with no oral malignant disease

Patients with oral premalignant disease

Patients with oral malignant disease

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Persons visiting oral and maxillofacial surgery department in Maastricht UMC or Radboud UMC who meet the inclusion criteria can be included.

You may qualify if:

  • Patients ≥18 years in case of oral malignancy or premalignant disease, ≥40 years in case of no malignant disease
  • Patients are (partially) dentate (≥20 teeth)
  • Patients who have given written informed consent to participate in this study

You may not qualify if:

  • Patients with a history of radiotherapy in head and neck region
  • Patients with a history of chemotherapy, immunotherapy or immunomodulating drugs
  • Patients with a previous malginancy in head and neck region
  • Edentulous patients (with or without implants)
  • Patients with removable (partial) dentures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Deptartment of Oral and Maxillofacial Surgery, Maastricht UMC+

Maastricht, Netherlands

RECRUITING

Department of Cranio- & Maxillofacial surgery, Radboud UMC

Nijmegen, Netherlands

RECRUITING

MeSH Terms

Conditions

Mouth NeoplasmsSquamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Head and Neck NeoplasmsNeoplasms by SiteNeoplasmsMouth DiseasesStomatognathic DiseasesCarcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Drs. L.A.A. Vaassen & Dr. E.R.C. Hagens

Study Record Dates

First Submitted

February 22, 2023

First Posted

March 13, 2023

Study Start

December 1, 2021

Primary Completion

July 1, 2024

Study Completion

December 1, 2024

Last Updated

March 13, 2023

Record last verified: 2023-03

Locations